06.01.03
Indication: Cholesterol levels in statin-treated patients
Source: New Functional Ingredients & Foods meeting held in April in Copenhagen, Denmark.
Research: The purpose of the study was to test whether Abacor, a newly developed dietary supplement containing isolated soy protein, phospholipids and fibers has an additional cholesterol lowering effect in patients treated with a lipid lowering drug from the group of 3-hydoxy-3-methylglutaryl coenzyme reductase inhibitors (statins) but having plasma concentrations above target values. Eligible for the study were patients treated with statins having a plasma low density lipoprotein (LDL) cholesterol concentration above 3 mmol/L. In total, 67 subjects were screened, 53 (79%) were eligible for participation and 49 subjects (15 women/34 men, 43-79 years) completed the study. All patients received their usual statin dose for six weeks followed by six weeks of statin + Abacor and finally six weeks of usual statin does.
Results: Plasma total cholesterol and LDL cholesterol concentrations were significantly lower after six weeks of combination treatment 5.5 mmol/L and 3.3 mmol/L, respectively, than the mean value of the concentrations after the two periods of six weeks statin monotherapy, 5.0 mmol/L and 3.6 mmol/L, respectively. No significant differences in plasma HDL cholesterol and triglyceride concentrations were found. Compliance to consumption of both Abacor® and statin was high, 95% and 98%, respectively. No significant differences in the number of adverse events were found between the combination period and the statin monotherapy periods.
Source: New Functional Ingredients & Foods meeting held in April in Copenhagen, Denmark.
Research: The purpose of the study was to test whether Abacor, a newly developed dietary supplement containing isolated soy protein, phospholipids and fibers has an additional cholesterol lowering effect in patients treated with a lipid lowering drug from the group of 3-hydoxy-3-methylglutaryl coenzyme reductase inhibitors (statins) but having plasma concentrations above target values. Eligible for the study were patients treated with statins having a plasma low density lipoprotein (LDL) cholesterol concentration above 3 mmol/L. In total, 67 subjects were screened, 53 (79%) were eligible for participation and 49 subjects (15 women/34 men, 43-79 years) completed the study. All patients received their usual statin dose for six weeks followed by six weeks of statin + Abacor and finally six weeks of usual statin does.
Results: Plasma total cholesterol and LDL cholesterol concentrations were significantly lower after six weeks of combination treatment 5.5 mmol/L and 3.3 mmol/L, respectively, than the mean value of the concentrations after the two periods of six weeks statin monotherapy, 5.0 mmol/L and 3.6 mmol/L, respectively. No significant differences in plasma HDL cholesterol and triglyceride concentrations were found. Compliance to consumption of both Abacor® and statin was high, 95% and 98%, respectively. No significant differences in the number of adverse events were found between the combination period and the statin monotherapy periods.